Articles

Will Accountable Care organizations have a positive impact on oncology and patients with cancer

Will Accountable Care organizations have a positive impact on oncology and patients with cancer

By Michael Kolodziej, MD

Accountable Care Organization

Dr. Michael Kolodziej explains how ACO's ability to improve cancer care is still unclear.

Safety Overview of the CLLM1 Trial: Lenalidomide Maintenance Therapy After Frontline Chemoimmunotherapy in High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Functional Evidence that Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The Combination of Alemtuzumab and Ofatumumab in Previously Untreated CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ublituximab plus TGR-1202 in Heavily Pretreated and High-Risk CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib in Relapsed/Refractory CLL After Allogeneic Stem-Cell Transplant

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Dinaciclib plus Ofatumumab in Patients with Relapsed/Refractory CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Ibrutinib versus Ofatumumab in Patients with Relapsed/Refractory CLL in the RESONATE Study

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

The FCR2 Regimen: A Phase 2 Study of FCR-Lite and Lenalidomide in Frontline CLL

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Idelalisib plus Rituximab for Relapsed CLL: Interim Analysis in Subpopulations with del17p and Other Adverse Prognostic Factors

ASH 2014 - CLL, ASH Highlights

Conference Correspondent

Page 206 of 330